Ogivri (Trastuzumab)
Breast Cancer
ApprovedCommercial
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Novartis | Acquisition |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Tamoxifen | Natco Pharma | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |